JP Morgan Chase’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,136,847
| Closed | -$2.1M | – | 7527 |
|
|
2023
Q1 | $2.1M | Buy |
1,136,847
+886,639
| +354% | +$1.1M | ﹤0.01% | 3500 |
|
|
2022
Q4 | $278K | Buy |
250,208
+141
| +0.1% | +$201 | ﹤0.01% | 4872 |
|
|
2022
Q3 | $585K | Sell |
250,067
-10,503
| -4% | -$37.2K | ﹤0.01% | 4356 |
|
|
2022
Q2 | $790K | Buy |
260,570
+36,186
| +16% | +$176K | ﹤0.01% | 4257 |
|
|
2022
Q1 | $1.52M | Sell |
224,384
-39,509
| -15% | -$282K | ﹤0.01% | 3962 |
|
|
2021
Q4 | $2.2M | Sell |
263,893
-28,532
| -10% | -$235K | ﹤0.01% | 3786 |
|
|
2021
Q3 | $2.17M | Sell |
292,425
-37,878
| -11% | -$235K | ﹤0.01% | 3728 |
|
|
2021
Q2 | $2.25M | Buy |
330,303
+165,028
| +100% | +$1.37M | ﹤0.01% | 3716 |
|
|
2021
Q1 | $1.7M | Buy |
165,275
+43,486
| +36% | +$476K | ﹤0.01% | 3838 |
|
|
2020
Q4 | $853K | Sell |
121,789
-4,018
| -3% | -$31.3K | ﹤0.01% | 4059 |
|
|
2020
Q3 | $1.03M | Sell |
125,807
-9,590
| -7% | -$59.5K | ﹤0.01% | 3625 |
|
|
2020
Q2 | $935K | Sell |
135,397
-15,341
| -10% | -$82.8K | ﹤0.01% | 3559 |
|
|
2020
Q1 | $716K | Sell |
150,738
-24,199
| -14% | -$139K | ﹤0.01% | 3625 |
|
|
2019
Q4 | $1.53M | Sell |
174,937
-185,828
| -52% | -$1M | ﹤0.01% | 3577 |
|
|
2019
Q3 | $1.2M | Buy |
360,765
+65,197
| +22% | +$261K | ﹤0.01% | 3727 |
|
|
2019
Q2 | $1.38M | Buy |
295,568
+15,125
| +5% | +$80.3K | ﹤0.01% | 3640 |
|
|
2019
Q1 | $1.74M | Sell |
280,443
-339,705
| -55% | -$1.64M | ﹤0.01% | 3425 |
|
|
2018
Q4 | $2.09M | Buy |
620,148
+180,119
| +41% | +$841K | ﹤0.01% | 3241 |
|
|
2018
Q3 | $2.86M | Buy |
440,029
+266,126
| +153% | +$1.98M | ﹤0.01% | 3199 |
|
|
2018
Q2 | $1.33M | Buy |
173,903
+22,488
| +15% | +$324K | ﹤0.01% | 3663 |
|
|
2018
Q1 | $3.38M | Sell |
151,415
-11,308
| -7% | -$251K | ﹤0.01% | 2893 |
|
|
2017
Q4 | $2.07M | Buy |
162,723
+120,523
| +286% | +$1.77M | ﹤0.01% | 3299 |
|
|
2017
Q3 | $649K | Sell |
42,200
-700
| -2% | -$9.9K | ﹤0.01% | 3722 |
|
|
2017
Q2 | $602K | Sell |
42,900
-64,178
| -60% | -$1.37M | ﹤0.01% | 3646 |
|
|
2017
Q1 | $2.35M | Buy |
+107,078
| New | +$2.27M | ﹤0.01% | 2945 |
|
Other funds holding JNCE
JP Morgan Chase's JNCE Position: Q2 2023 in Review
JP Morgan Chase sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 1,136,847 shares — an estimated $2.1M sold.
JP Morgan Chase first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $3.38M in Q1 2018. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- JP Morgan Chase reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- JP Morgan Chase sold 1,136,847 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $2.1M.
- JP Morgan Chase first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
- JP Morgan Chase's Jounce Therapeutics, Inc. Common Stock position peaked at $3.38M in Q1 2018.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on JP Morgan Chase's 13F filing for Q2 2023, filed 11 Aug 2023.